TScan Therapeutics highlights push into in vivo-engineered TCR-T cell therapy for solid tumors in corporate presentation

Reuters2026/09/02 11:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

TScan outlined a strategic pivot toward in vivo-engineered TCR-T cell therapies for solid tumors, centered on a T-cell targeted lentiviral platform.
Two in vivo TCR-T candidates advanced into IND-enabling work, prioritizing PRAME and MAGE-A4 programs for solid tumor indications.
Key timeline: preclinical data and regulatory updates in Q1 2027, first IND filing in Q3 2027, Phase 1 trial start in Q4 2027.
Phase 3 solid tumor study paused to allow data to mature, while the company pursues external manufacturing and a strategic partnership.
Heme malignancies and autoimmunity programs put on hold pending partnership, with patients continuing follow-up in ALLOHA and ALLOHA-2 studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

TScan Therapeutics highlights push into in vivo-engineered TCR-T cell therapy for solid tumors in corporate presentation

You may also like

Crypto prices